Further Insights from Scientific Advisory Board Meeting – Confirms the Potential of Lumito’s Innovative Solution for Quantitative Tissue Analysis
At Lumito’s Scientific Advisory Board (SAB) meeting held on June 9, the SAB confirmed the uniqueness and potential of Lumito’s innovative solution, Scizys, for quantitative tissue analysis. Additionally, the advisors were unified in the view that Lumito has a product that will meet the needs of the pharmaceutical industry. The SAB, where a few have […]
Lumito’s Scientific Advisory Board Meeting Held and Additional Key Opinion Leader Joins
Following the establishment of its Scientific Advisory Board (SAB) announced on 5 June 2025, the SAB held a meeting this week, where the uniqueness of Lumito’s solution, Scizys, was confirmed and reaffirmed as a promising technology with the potential to lead the way in quantitative tissue analysis and pathology. Lumito are pleased to announce that […]
Lumito establishes Scientific Advisory Board with leading international experts in drug development, pathology, and oncology
Lumito has established a Scientific Advisory Board (SAB) to primarily support its ongoing commercialisation and, in the longer term, to strengthen the company’s strategic efforts toward a product for clinical use. The board comprises globally recognised experts in pathology, diagnostics, oncology, digitalisation, and drug development, with extensive experience spanning academia, healthcare, and the pharmaceutical industry. […]
Lumito featured at AACR 2025
The AACR Annual Meeting (American Association for Cancer Research) is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya’s Spotlight Theatre, […]
Lumito launches new website – highlighting increasing objectivity in tissue analysis
Lumito, a leading medical technology company focused on tissue analysis, is launching a new website today, centered around the core message: "Increasing objectivity in tissue analysis." "Our new website is a direct result of insights gathered from users and partners," says CEO Sanna Wallenborg. “There has been a clear need to better clarify and deepen […]
Lumito launches new image visualisation and analysis software in partnership with Katana Labs
We are excited to announce that the partnership between Lumito and Katana Labs has resulted in a customised analysis software solution tailored specifically for Lumito’s customers. Lumito and Katana Labs are launching an innovative, cloud-based image analysis and visualisation software. The new solution is specifically optimised for Lumito’s unique Scizys tissue imaging technology, which combines […]
Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery
We are excited to announce a collaboration between Lumito and Concept Life Sciences, a CRO (contract research organisation) based in UK, to enhance tissue analysis in drug discovery and development. This joint project will focus on evaluating and optimising Lumito’s innovative product Scizys, within Concept Life Sciences’ cutting-edge research service. This collaboration is more than […]
Lumito and Truly Labs join forces to drive innovation and enhanced competitiveness in tissue analysis
We are excited to announce that Lumito and Truly Labs are joining forces in a strategic partnership to develop innovative, value-driven solutions that provide both companies with a competitive edge in tissue analysis. “We are truly happy about this partnership where we will work together to improve the quality and objectivity of tissue analysis. Combining […]
Members of Lumitos board and management team intend to exercise warrants of series TO6
Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand. The board and management team intends to exercise warrants, directly or via companies, according to the following: Kerstin Jakobsson (Chair of the Board) – […]
The last day of trading with the warrants of series TO6 in Lumito AB is today, November 12, 2024
Today, November 12, 2024, is the last day of trading with the warrants of series TO6 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including November 15, 2024. Each warrant of series TO6 gives the owner the right to subscribe for one (1) new share […]
